Found 285 articles for: "biologics"
CME/CE: ABOUT FACE: Navigating Neuromodulators and Injection Techniques for Optimal Results
April 2020 | Volume 19 | Issue 4 | Supplement Individual Articles | 300 | Copyright © April 2020
Interest in the cosmetic use of neuromodulators for facial rejuvenation is increasing among physicians, other practitioners, and patients alike, and an expanding array of formulations and reported app...
Read MoreIs the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?
April 2020 | Volume 19 | Issue 4 | Features | 436 | Copyright © April 2020
Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?...
Read MoreCME: Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update
April 2020 | Volume 19 | Issue 4 | Supplement Individual Articles | 35 | Copyright © April 2020
Since initial US Food and Drug Administration approval of botulinum toxin type A (BoNT-A) for aesthetic use in 2002, clinical evidence and experience with BoNT-A and understanding of facial anatomy ha...
Read MoreHalobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
April 2020 | Volume 19 | Issue 4 | Original Article | 389 | Copyright © April 2020
Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/taz...
Read MoreRecapture Rate of Brodalumab in Patients With a Lapse in Treatment
April 2020 | Volume 19 | Issue 4 | Original Article | 384 | Copyright © April 2020
The National Psoriasis Foundation has emphasized the importance of achieving skin clearance targets throughout the course of treatment. However, patients with psoriasis often stop and restart treatmen...
Read MoreTumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn’s Disease Patient Successfully Treated with Ustekinumab
March 2020 | Volume 19 | Issue 3 | Case Reports | 328 | Copyright © March 2020
Background: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that...
Read MoreAtopic Dermatitis: A Review of Current Diagnostic Criteria and a Proposed Update to Management
March 2020 | Volume 19 | Issue 3 | Original Article | 244 | Copyright © March 2020
The diagnosis of atopic dermatitis (AD) remains primarily a clinical diagnosis, in which several clinical signs and symptoms including pruritus, the presence and location of skin lesions, and a person...
Read MoreEfficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis
March 2020 | Volume 19 | Issue 3 | Original Article | 306 | Copyright © March 2020
Psoriasis is a chronic, systemic disease with features suggestive of autoimmune dysregulation. Patients with psoriasis vulgaris frequently experience systemic comorbidities, including cardiovascular a...
Read MoreReal World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
March 2020 | Volume 19 | Issue 3 | Case Reports | 316 | Copyright © March 2020
Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life....
Read MoreEffect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
February 2020 | Volume 19 | Issue 2 | Original Article | 121 | Copyright © February 2020
OBJECTIVE: Investigate the effect of fixed-combination calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) foam on target lesion severity in plaque psoriasis.
DESIGN: Post-hoc a...
Read MoreReal-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab
February 2020 | Volume 19 | Issue 2 | Original Article | 132 | Copyright © February 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune dermatologic condition that manifests with scaly, erythematous plaques. It has a significantly negative effect on patient quality o...
Read MoreManagement of Residual Psoriasis in Patients on Biologic Treatment
February 2020 | Volume 19 | Issue 2 | Original Article | 188 | Copyright © February 2020
While biologics are highly effective, most psoriasis patients do not achieve...
Read MoreClinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
February 2020 | Volume 19 | Issue 2 | Original Article | 138 | Copyright © February 2020
The interleukin-17 (IL-17) pathway plays a crucial role in the development of psoriasis. Briefly, naive T cells differentiate into helper ...
Read MoreRapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies
January 2020 | Volume 19 | Issue 1 | Case Reports | 86 | Copyright © January 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune condition involving a dysregulated inflammatory response of the interleukin (IL) 23/T-helper (Th)-17 pathway. Greater understanding...
Read MoreGrowing Patient Education in Dermatology: An Upside-Down Tree Analogy for Immunomodulatory Therapies
January 2020 | Volume 19 | Issue 1 | Editorials | 104 | Copyright © January 2020
As patient autonomy gains momentum in the era of readily accessible health information, dermatologists bear a growing responsibility in patient education. With the rapid evolution and development of t...
Read MoreNon-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
October 2019 | Volume 18 | Issue 10 | Editorials | 1059 | Copyright © October 2019
Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especiall...
Read MoreHalobetasol 0.01% Lotion in the Treatment of Moderate- to-Severe Plaque Psoriasis of the Lower Extremities
October 2019 | Volume 18 | Issue 10 | Original Article | 1029 | Copyright © October 2019
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safet...
Read MoreImpact of Psoriasis on Women
September 2019 | Volume 18 | Issue 9 | Features | 950 | Copyright © September 2019
Psoriasis is a common, chronic inflammatory skin disease that can affect any part of the body. It is a highly visible condition with symptoms that include the appearance of red, thick, scaly patches o...
Read MoreInvention in Dermatology: A Review
September 2019 | Volume 18 | Issue 9 | Original Article | 904 | Copyright © September 2019
Dermatologists are among the most inventive physicians, trained in the multiple disciplines of medical dermatology, surgical dermatology, and dermatopathology. Many of the advances in de...
Read MoreThe Paradoxical Induction of Crohn’s Disease Following Treatment of Psoriatic Arthritis With Etanercept
August 2019 | Volume 18 | Issue 8 | Case Reports | 832 | Copyright © August 2019
Introduction: While psoriasis, psoriatic arthritis, and Crohn’s Disease (CD) all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancie...
Read More